Resveratrol and cancer: Challenges for clinical translation

Area of Science:

• * Pharmacology and Therapeutics
• * Oncology
• * Natural Products Chemistry

Background:

• * Resveratrol, a grape antioxidant, has demonstrated health benefits in preclinical models.
• * Extensive research explores resveratrol's potential in cancer management.
• * Clinical translation of resveratrol's anticancer effects is limited by numerous challenges.

Purpose of the Study:

• * To review the challenges hindering the clinical translation of resveratrol as an anticancer drug.
• * To examine metabolic and mechanistic issues affecting in vivo efficacy.
• * To explore current research efforts addressing these translation barriers.

Main Methods:

• * Comprehensive review of preclinical studies on resveratrol's biological effects.
• * Analysis of published data and previous clinical trials.
• * Examination of challenges in resveratrol's in vivo application and mechanism of action.

Main Results:

• * Significant preclinical data supports resveratrol's anticancer potential.
• * Clinical translation is impeded by metabolic instability and incomplete understanding of mechanisms.
• * Various public and private research initiatives are underway to overcome these obstacles.

Conclusions:

• * Overcoming metabolic and mechanistic challenges is crucial for resveratrol's clinical success in cancer management.
• * Further research and strategic development are needed to bridge the gap between preclinical findings and patient outcomes.
• * Addressing these issues is essential for realizing resveratrol's therapeutic potential in oncology.